PO.MCB10.02 · 分子与细胞生物学
TUG1介导的复制应激调控是膀胱癌潜在的可利用弱点
TUG1-mediated replication stress regulation as a potential vulnerability in bladder cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
膀胱癌(BCa)表现出显著的基因组不稳定性,由APOBEC突变过程、TP53、RB1、ERCC2和ATM的反复改变以及慢性复制应激(RS)所驱动。这类富含RS的基因组需要缓冲R环积累和复制相关DNA损伤的机制以维持增殖。我们此前已证明,长链非编码RNA(lncRNA)牛磺酸上调基因1(TUG1)是一种由ATR-CHK1信号诱导的RS响应性lncRNA,对于维持多种癌症类型的基因组稳定性至关重要。我们先前的研究揭示,TUG1促进R环的解析,并在基因毒性条件下支持肿瘤细胞存活。鉴于膀胱癌本质上以APOBEC驱动的突变、DNA修复缺陷和持续的RS为特征,我们假设膀胱癌细胞可能依赖于TUG1介导的R环调控。为验证这一可能性,我们分析了TCGA-BLCA数据,发现肿瘤组织中TUG1表达较邻近正常尿路上皮显著升高。对临床膀胱癌标本的RNA-FISH进一步证实TUG1在恶性上皮区室内表达较高。使用靶向TUG1的反义寡核苷酸(TUG1-ASO)进行的功能实验表明,可有效清除内源性TUG1,降低细胞活力,并下调细胞周期相关转录本。TUG1的缺失还诱导了复制应激和DNA损伤标志物,包括pRPA32和gammaH2AX,并使膀胱癌细胞对RS诱导条件敏感化。综上所述,这些发现表明膀胱癌细胞依赖TUG1在高RS压力下维持增殖。治疗性清除TUG1可破坏这一适应性机制并损害肿瘤细胞生长,支持TUG1作为膀胱癌潜在治疗靶点。
查看英文原文 English abstract
Bladder cancer (BCa) displays marked genomic instability driven by APOBEC mutational processes, recurrent alterations in TP53, RB1, ERCC2, and ATM, and chronic replication stress (RS). Such RS-rich genomes require mechanisms that buffer R-loop accumulation and replication-associated DNA damage to sustain proliferation. We have previously demonstrated that the long non-coding RNA (lncRNA) Taurine upregulated gene 1 (TUG1) is a RS-responsive lncRNA induced by ATR-CHK1 signaling and essential for maintaining genome stability across multiple cancer types. Our prior work revealed that TUG1 promotes R-loop resolution and supports tumor cell survival under genotoxic conditions. Given that BCa is intrinsically defined by APOBEC-driven mutagenesis, DNA repair defects, and persistent RS, we hypothesized that BCa cells may rely on TUG1-mediated R-loop regulation. To evaluate this possibility, we analyzed TCGA-BLCA and found significantly elevated TUG1 expression in tumor tissues compared with adjacent normal urothelium. RNA-FISH of clinical BCa specimens further confirmed higher expression of TUG1 within malignant epithelial compartments. Functional assays using a TUG1-targeting antisense oligonucleotide (TUG1-ASO) demonstrated efficient depletion of endogenous TUG1, reduced cell viability, and downregulation of cell-cycle-related transcripts. Loss of TUG1 also induced replication stress and DNA damage markers, including pRPA32 and gammaH2AX, and sensitized BCa cells to RS-inducing conditions.Taken together, these findings indicate that BCa cells depend on TUG1 to maintain proliferation under high RS pressure. Therapeutic depletion of TUG1 disrupts this adaptive mechanism and impairs tumor cell growth, supporting TUG1 as a potential therapeutic target in BCa.
利益披露 Disclosure
A. Ishiyama, None..
M. Suzuki, None..
K. Shinjo, None.
S. Akamatsu,
Tosoh Corporation ).
Janssen Pharmaceutical K.K. Other, Honorarium.
Bayer Yakuhin, Ltd. Other, Honorarium.
Takeda Pharmaceutical Co., Ltd. Other, Honorarium.
Astellas Pharma Inc. Other, Honorarium.
Novartis Pharma K.K. Other, Honorarium.
Pfizer Japan Inc. Other, Honorarium.
MSD K.K. Other, Honorarium.
CHUGAI PHARMACEUTICAL CO., LTD. Other, Honorarium.
ONO PHARMACEUTICAL CO., LTD. Other, Honorarium.
Y. Kondo,
NANO MRNA Co., Ltd. ).